Tags

Type your tag names separated by a space and hit enter

Venomics of the poorly studied hognosed pitvipers Porthidium arcosae and Porthidium volcanicum.
J Proteomics. 2021 10 30; 249:104379.JP

Abstract

We report the first proteomics analyses of the venoms of two poorly studied snakes, the Manabi hognosed pitviper Porthidium arcosae endemic to the western coastal province of Manabí (Ecuador), and the Costa Rican hognosed pitviper P. volcanicum with distribution restricted to South Pacific Costa Rica and western Panamá. These venom proteomes share a conserved compositional pattern reported in four other congeneric species within the clade of South American Porthidium species, P. nasutum, P. lansbergii, P. ophryomegas, and P. porrasi. The paraspecific immunorecognition profile of antivenoms produced in Costa Rica (ICP polyvalent), Perú (Instituto Nacional de Salud) and Brazil (soro antibotrópico pentavalente, SAB, from Instituto Butantan) against the venom of P. arcosae was investigated through a third-generation antivenomics approach. The maximal venom-binding capacities of the investigated antivenoms were 97.1 mg, 21.8 mg, and 25.7 mg of P. arcosae venom proteins per gram of SAB, ICP, and INS-PERU antibody molecules, respectively, which translate into 28.4 mg, 13.1 mg, and 15.2 mg of total venom proteins bound per vial of SAB, ICP, and INS-PERU AV. The antivenomics results suggest that 21.8%, 7.8% and 6.1% of the SAB, ICP, and INS-PERU antibody molecules recognized P. arcosae venom toxins. The SAB antivenom neutralized P. arcosae venom's lethality in mice with an ED50 of 31.3 mgV/g SAB AV. This preclinical neutralization paraspecificity points to Brazilian SAB as a promising candidate for the treatment of envenomings by Ecuadorian P. arcosae. BIOLOGICAL SIGNIFICANCE: Assessing the preclinical efficacy profile of antivenoms against homologous and heterologous medically relevant snake venoms represents an important goal towards defining the biogeographic range of their clinical utility. This is particularly relevant in regions, such as Mesoamerica, where a small number of pharmaceutical companies produce antivenoms against the venoms of a small number of species of maximum medical relevance among the local rich herpetofauna, leaving a wide range of snakes of secondary medical relevance, but also causing life-threatening human envenomings without nominal clinical coverage. This work is part of a larger project aiming at mapping the immunological characteristics of antivenoms generated in Latin American countries towards venoms of such poorly studied snakes of the local and neighboring countries' herpetofauna. Here we report the proteomics characterization of the Manabi hognosed pitviper Porthidium arcosae endemic to the western coastal province of Manabí (Ecuador), and the Costa Rican hognosed pitviper P. volcanicum with distribution restricted to southwestern Costa Rica, the antivenomics assessment of three bothropoid commercial antivenoms produced in Costa Rica, Perú, and Brazil against the venom components of P. arcosae, and the in vivo capacity of the Brazilian soro antibotrópico pentavalente (SAB) from Instituto Butantan to neutralize the murine lethality of P. arcosae venom. The preclinical paraspecific ED50 of 31.3 mg of P. arcosae venom per gram of antivenom points to Brazilian SAB as a promising candidate for the treatment of envenomings by the Manabi hognosed pitviper P. arcosae.

Authors+Show Affiliations

Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica.Laboratorio de Venómica Evolutiva y Traslacional, Consejo Superior de Investigaciones Científicas, Valencia, Spain. Electronic address: libia.sanz@ibv.csic.es.Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica. Electronic address: Fabian.Bonilla@ucr.ac.cr.Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica; Centro Investigaciones, Biodiversidad y Ecología Tropical, Universidad de Costa Rica, San José, Costa Rica. Electronic address: mahmood.sasa@ucr.ac.cr.Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica. Electronic address: bruno.lomonte@ucr.ac.cr.College of Biochemistry and Pharmacy, Faculty of Chemical Sciences, University of Cuenca, Cuenca, Ecuador. Electronic address: fausto.zaruma@ucuenca.edu.ec.Instituto Nacional de Investigación en Salud Pública (INSPI), Guayaquil, Ecuador. Electronic address: mteran@inspi.gob.ec.Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica.Laboratorio de Venómica Evolutiva y Traslacional, Consejo Superior de Investigaciones Científicas, Valencia, Spain. Electronic address: jcalvete@ibv.csic.es.Centro de Estudos de Biomoléculas Aplicadas a Saúde CEBio/FIOCRUZ/UNIR, Rua da Beira 7671, Lagoa, CEP 76820-245 Porto Velho, Rondônia, Brazil; Programa de Pós-graduação em Biologia Experimental (PGBIOEXP), Universidade Federal de Rondônia (UNIR), Porto Velho, Brazil; Programa de Pós-graduação em Biodiversidade e Biotecnologia, rede BIONORTE, Porto Velho, RO, Brazil. Electronic address: cleopatra@unir.br.College of Biochemistry and Pharmacy, Faculty of Chemical Sciences, University of Cuenca, Cuenca, Ecuador. Electronic address: saulo.da.silva@ucuenca.edu.ec.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34534714

Citation

Ruiz-Campos, Marco, et al. "Venomics of the Poorly Studied Hognosed Pitvipers Porthidium Arcosae and Porthidium Volcanicum." Journal of Proteomics, vol. 249, 2021, p. 104379.
Ruiz-Campos M, Sanz L, Bonilla F, et al. Venomics of the poorly studied hognosed pitvipers Porthidium arcosae and Porthidium volcanicum. J Proteomics. 2021;249:104379.
Ruiz-Campos, M., Sanz, L., Bonilla, F., Sasa, M., Lomonte, B., Zaruma-Torres, F., Terán, M., Fernández, J., Calvete, J. J., Caldeira, C. A. S., & Da Silva, S. L. (2021). Venomics of the poorly studied hognosed pitvipers Porthidium arcosae and Porthidium volcanicum. Journal of Proteomics, 249, 104379. https://doi.org/10.1016/j.jprot.2021.104379
Ruiz-Campos M, et al. Venomics of the Poorly Studied Hognosed Pitvipers Porthidium Arcosae and Porthidium Volcanicum. J Proteomics. 2021 10 30;249:104379. PubMed PMID: 34534714.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Venomics of the poorly studied hognosed pitvipers Porthidium arcosae and Porthidium volcanicum. AU - Ruiz-Campos,Marco, AU - Sanz,Libia, AU - Bonilla,Fabián, AU - Sasa,Mahmood, AU - Lomonte,Bruno, AU - Zaruma-Torres,Fausto, AU - Terán,Maria, AU - Fernández,Julián, AU - Calvete,Juan J, AU - Caldeira,Cleópatra A S, AU - Da Silva,Saulo L, Y1 - 2021/09/15/ PY - 2021/08/11/received PY - 2021/09/07/revised PY - 2021/09/07/accepted PY - 2021/9/18/pubmed PY - 2021/11/3/medline PY - 2021/9/17/entrez KW - Antivenomics KW - Genus Porthidium KW - Latin American antivenoms KW - Porthidium arcosae KW - Porthidium volcanicum KW - Snake venomics SP - 104379 EP - 104379 JF - Journal of proteomics JO - J Proteomics VL - 249 N2 - We report the first proteomics analyses of the venoms of two poorly studied snakes, the Manabi hognosed pitviper Porthidium arcosae endemic to the western coastal province of Manabí (Ecuador), and the Costa Rican hognosed pitviper P. volcanicum with distribution restricted to South Pacific Costa Rica and western Panamá. These venom proteomes share a conserved compositional pattern reported in four other congeneric species within the clade of South American Porthidium species, P. nasutum, P. lansbergii, P. ophryomegas, and P. porrasi. The paraspecific immunorecognition profile of antivenoms produced in Costa Rica (ICP polyvalent), Perú (Instituto Nacional de Salud) and Brazil (soro antibotrópico pentavalente, SAB, from Instituto Butantan) against the venom of P. arcosae was investigated through a third-generation antivenomics approach. The maximal venom-binding capacities of the investigated antivenoms were 97.1 mg, 21.8 mg, and 25.7 mg of P. arcosae venom proteins per gram of SAB, ICP, and INS-PERU antibody molecules, respectively, which translate into 28.4 mg, 13.1 mg, and 15.2 mg of total venom proteins bound per vial of SAB, ICP, and INS-PERU AV. The antivenomics results suggest that 21.8%, 7.8% and 6.1% of the SAB, ICP, and INS-PERU antibody molecules recognized P. arcosae venom toxins. The SAB antivenom neutralized P. arcosae venom's lethality in mice with an ED50 of 31.3 mgV/g SAB AV. This preclinical neutralization paraspecificity points to Brazilian SAB as a promising candidate for the treatment of envenomings by Ecuadorian P. arcosae. BIOLOGICAL SIGNIFICANCE: Assessing the preclinical efficacy profile of antivenoms against homologous and heterologous medically relevant snake venoms represents an important goal towards defining the biogeographic range of their clinical utility. This is particularly relevant in regions, such as Mesoamerica, where a small number of pharmaceutical companies produce antivenoms against the venoms of a small number of species of maximum medical relevance among the local rich herpetofauna, leaving a wide range of snakes of secondary medical relevance, but also causing life-threatening human envenomings without nominal clinical coverage. This work is part of a larger project aiming at mapping the immunological characteristics of antivenoms generated in Latin American countries towards venoms of such poorly studied snakes of the local and neighboring countries' herpetofauna. Here we report the proteomics characterization of the Manabi hognosed pitviper Porthidium arcosae endemic to the western coastal province of Manabí (Ecuador), and the Costa Rican hognosed pitviper P. volcanicum with distribution restricted to southwestern Costa Rica, the antivenomics assessment of three bothropoid commercial antivenoms produced in Costa Rica, Perú, and Brazil against the venom components of P. arcosae, and the in vivo capacity of the Brazilian soro antibotrópico pentavalente (SAB) from Instituto Butantan to neutralize the murine lethality of P. arcosae venom. The preclinical paraspecific ED50 of 31.3 mg of P. arcosae venom per gram of antivenom points to Brazilian SAB as a promising candidate for the treatment of envenomings by the Manabi hognosed pitviper P. arcosae. SN - 1876-7737 UR - https://www.unboundmedicine.com/medline/citation/34534714/Venomics_of_the_poorly_studied_hognosed_pitvipers_Porthidium_arcosae_and_Porthidium_volcanicum_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1874-3919(21)00278-5 DB - PRIME DP - Unbound Medicine ER -